ECO 2026: EASO Updates Obesity Drug Guidance Algorithm Tags GLP-1 agonists Read more about ECO 2026: EASO Updates Obesity Drug Guidance Algorithm
Estimated Oral Semaglutide Exposure Linked to Weight Loss and GI Side Effects Tags GLP-1 agonists Read more about Estimated Oral Semaglutide Exposure Linked to Weight Loss and GI Side Effects
Dapagliflozin Linked to Preserved HRV During GLP-1 RA Therapy Tags SGLT-2 Inhibitor Read more about Dapagliflozin Linked to Preserved HRV During GLP-1 RA Therapy
GLP-1 RAs Linked to Lower Mortality in Breast Cancer Tags GLP-1 agonists Read more about GLP-1 RAs Linked to Lower Mortality in Breast Cancer
Dapagliflozin-Linagliptin Combination Improved TIR in T2DM Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about Dapagliflozin-Linagliptin Combination Improved TIR in T2DM
SGLT2 Inhibitors Show No Increased Cancer Risk Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Show No Increased Cancer Risk
AID Increased Time-in-Range in Children Younger Than 7 Years Tags Diabetic ketoacidosis Hypoglycemia hBA1c Continuous glucose monitoring (CGM) Read more about AID Increased Time-in-Range in Children Younger Than 7 Years
MACE Rates With Semaglutide Were Similar Across Weight Loss Strata Tags GLP-1 agonists Read more about MACE Rates With Semaglutide Were Similar Across Weight Loss Strata
GLP-1 Therapy Lowered MACE and Hypoglycemia Risk in T1DM Tags Coronary artery disease Myocardial infarction GLP-1 agonists Read more about GLP-1 Therapy Lowered MACE and Hypoglycemia Risk in T1DM
ACC.26: AF Rates Were Lower Among GLP-1 Users With Advanced CKD Tags Atrial Fibrillation SGLT-2 Inhibitor Read more about ACC.26: AF Rates Were Lower Among GLP-1 Users With Advanced CKD